GoodRx profit margin GDRX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- 2.1%
- Operating margin, 12 months
- 9.5%
- Net margin on a year earlier
- −2.3 pts
- Peer median
- 9.3%
Over the twelve months to Jun 30, 2026, GoodRx kept 2.1% of its revenue as net profit, with an operating margin of 9.5% and a gross margin of 90.8%.
Five years earlier its net margin was −50.0%.
The median for 10 application software stocks of a similar size is 9.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 3.8% | 11.0% | 92.8% |
| FY2024 | 2.1% | 8.3% | 93.9% |
| FY2023 | −1.2% | −3.6% | 91.1% |
| FY2022 | −4.3% | 0.2% | 91.5% |
| FY2021 | −3.4% | 1.8% | 93.7% |
| FY2020 | −53.3% | −50.1% | 94.6% |
| FY2019 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 2.1% | −2.3 pts | 9.5% | |
| Q1 FY26 | 2.6% | −1.0 pts | 9.9% | |
| Q4 FY25 | 3.8% | +1.8 pts | 11.0% | |
| Q3 FY25 | 4.0% | +6.0 pts | 10.4% | |
| Q2 FY25 | 4.3% | +11.9 pts | 11.1% | |
| Q1 FY25 | 3.6% | +4.4 pts | 10.3% | |
| Q4 FY24 | 2.1% | +3.3 pts | 8.3% | |
| Q3 FY24 | −2.1% | −4.1 pts | 3.7% | |
| Q2 FY24 | −7.6% | −9.2 pts | −3.8% | |
| Q1 FY24 | −0.9% | +5.6 pts | −4.0% | |
| Q4 FY23 | −1.2% | +3.1 pts | −3.6% | |
| Q3 FY23 | 2.0% | +10.9 pts | −0.9% |
Against its peers
Companies in Software - Application nearest GoodRx's size, closest first, today.
| Company | Profit margin |
|---|---|
| GDRXGoodRx | 2.1% |
| LZLegalzoom.Com | 2.1% |
| UPWKUpwork | 12.9% |
| HSTMHealthstream | 6.6% |
| EVEREverQuote | 15.2% |
| TASKTaskUs | 8.8% |
| EVTCEVERTEC | 9.8% |
| YEXTYext | 5.9% |
| MNTNMNTN | 18.0% |
| INODInnodata | 14.7% |
| NRDSNerdwallet | 7.6% |
| Peer median | 9.3% |
Where GoodRx ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on GoodRx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.